Press-release for stocks related to fda for A

Prices are updated after-hours

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Published: 2023-11-14 (Crawled : 14:30) - biospace.com/
A | $137.49 -1.23% -0.36% 1.6M

| 29.54% | O: 2.18% H: 0.0% C: 0.0%
fda approval

Teva Uses the Agilent TRS100 to Achieve Regulatory Milestone for Content Uniformity Testing with the FDA
Published: 2022-07-05 (Crawled : 13:00) - biospace.com/
A | $137.49 -1.23% -0.36% 1.6M

| 17.2% | O: -0.86% H: 2.48% C: 2.39%
trs100 fda milestone

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer
Published: 2021-10-13 (Crawled : 23:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

| 217.49% | O: 0.55% H: 1.64% C: 1.01%
A | $137.49 -1.23% -0.36% 1.6M

| -5.91% | O: 0.76% H: 1.21% C: 0.76%
fda risk cancer breast cancer approval diagnostic

FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression ≥1%)
Published: 2021-06-11 (Crawled : 18:03) - fda.gov
A | $137.49 -1.23% -0.36% 1.6M

| -2.7% | O: 0.21% H: 0.17% C: 0.12%
approval fda fda approval nivolumab

Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)
Published: 2021-02-22 (Crawled : 22:00) - biospace.com/
A | $137.49 -1.23% -0.36% 1.6M

| 9.72% | O: -0.73% H: 0.17% C: -1.95%
fda lung cancer fda approval cancer approval

62%

38%

CSSE 4 | $0.4323 183.85% 64.77% 220M

BOF | $1.99 70.09% 41.21% 110M

ILAG | $0.51 6.03% 40.62% 1.7M

LICN | $0.941 68.04% 40.49% 15M

AMST | $3.31 65.5% 39.58% 70M

MTC | $3.615 61.38% 38.04% 9.3M

WIMI | $1.15 58.53% 36.92% 19M

AIH | $0.45 12.5% 30.92% 320K

MULN | News | $3.78 38.46% 27.78% 13M

RILY | $29.86 37.48% 27.26% 12M

Save your searches and get alerts when important news are released.